Dermatomyositis/polymyositis and anti-TNF-α therapies: a literature review

References

• Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch. Dermatol. 146, 26–30 (2010).
   PubMedGoogle Scholar
• Martin N, Li CK, Wedderburn LR. Juvenile dermatomyositis: new insights and new treatment strategies. Ther. Adv. Musculoskelet. Dis. 4(1), 41–50 (2012).
   PubMedGoogle Scholar
• Strowd LC, Jorizzo JL. Review of dermatomyositis: establishing the diagnosis and treatment algorithm. J. Dermatolog. Treat. (2012) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Brown VE, Pilkington CA, Feldman, BM, Davidson JE. An international consensus survey of the diagnostic criteria for juvenile dermato- myositis (JDM). Rheumatology 45(8), 990–993 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst. Rev. 15(8), (2012).
   Google Scholar
• Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann. Neurol. 70(3), 427–436 (2011).
   PubMed Web of Science ®Google Scholar
• Giovanna Brunasso AM, Fancelli L, Massone C. Etanercept as steroid-sparing agent in dermatomyositis. Ann. Neurol. 70(4), 670–671 (2011).
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 59(2), 222–226 (2008).
   PubMed Web of Science ®Google Scholar
• Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 59(7), 989–995 (2008).
   PubMed Web of Science ®Google Scholar
• Stringer E, Bohnsack J, Bowyer, SL et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J. Rheumatol.? 37(9), 1953–1961 (2010).
   PubMed Web of Science ®Google Scholar
• Martin N, Wedderburn LR, Pilkington CA, Davidson JE. A survey of current practice in the management of Juvenile Dermatomyositis in the UK and Ireland. Abstract from the 17th Paediatric Rheumatology European Society Congress. Clin. Exp. Rheumatol. 29( Suppl.), 372 (2011).
   Google Scholar
• Ramanan AV, Campbell-Webster N, Ota S et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 52(11), 3570–3578 (2005).
   PubMed Web of Science ®Google Scholar
• Hasija R, Pistorio A, Ravelli A et al. Pediatric Rheumatology International Trials Organization. Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onse disease and in those experiencing disease flare: an international multicenter PRINTO study. Arthritis Rheum. 63(10), 3142–3152 (2011).
   PubMedGoogle Scholar
• Dagher R, Desjonquères M, Duquesne A et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol. Int. 32(3), 711–716 (2012).
   PubMed Web of Science ®Google Scholar
• Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin. Rheumatol. 27(11), 1469–1471 (2008).
   PubMed Web of Science ®Google Scholar
• Holzer U, van Royen-Kerkhof A, van der Torre et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand. J. Rheumatol. 39(1), 88–92 (2010).
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R et al. RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65(2), 314–324 (2013).
   PubMed Web of Science ®Google Scholar
• Pachman LM, Fedczyna TO, Lechman TS, Lutz J. Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity. Curr. Rheumatol. Rep. 3(5), 379–86 (2001).
   PubMedGoogle Scholar
• Chinoy H, Salway F, John S et al. UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology (Oxford) 46(9), 1411–1416 (2007).
   PubMed Web of Science ®Google Scholar
• Lutz J, Huwiler KG, Fedczyna T et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin. Immunol. 103(3 Pt 1), 260–263 (2002).
   PubMed Web of Science ®Google Scholar
• Morita R, Schmitt N, Bentebibel SE et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34(1), 108–121 (2011).
   PubMed Web of Science ®Google Scholar
• Cappelletti, F. Baggi, F. Zolezzi et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myo- pathies. Neurology 76(24), 2079–2088, (2011).
   PubMed Web of Science ®Google Scholar
• De Paepe B, Creus KK, De Bleecker JL. The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin. Dev. Immunol. 369432 (2012).
   PubMedGoogle Scholar
• Dastmalchi M, Grundtman C, Alexanderson H et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 67, 1670–1677 (2008).
   PubMed Web of Science ®Google Scholar
• Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J. Rheumatol. 33(9), 1802–1804 (2006).
   PubMed Web of Science ®Google Scholar
• Roddy E, Courtney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology ( Oxford). 41(10), 1194–1195 (2002).
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann. Rheum. Dis. 65(9), 1233–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, Barrera P et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur. Neurol. 50(1), 10–15 (2003).
   PubMed Web of Science ®Google Scholar
• Selva-O'Callaghan A, Martínez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarrés M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 43(9), 1196–1197 (2004).
   PubMed Web of Science ®Google Scholar
• Uthman I, El-Sayad J. Refractory polymyositis responding to infliximab. Rheumatology (Oxford) 43(9), 1198–1199 (2004).
   PubMed Web of Science ®Google Scholar
• Korkmaz C, Temiz G, Cetinbas F, Büyükkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford) 43(7), 937–938 (2004).
   PubMed Web of Science ®Google Scholar
• Choi KH, Yoo WH. Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis. Rheumatol. Int. 29(4), 463–466 (2009).
   PubMed Web of Science ®Google Scholar
• Sprott H, Glatzel M, Michel BA. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 43(4), 524–526 (2004).
   PubMed Web of Science ®Google Scholar
• Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin. Rheumatol. 26(7), 1186–1188 (2007).
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur. Neurol. 52(1), 61–63 (2004).
   PubMed Web of Science ®Google Scholar
• Klein R, Rosenbach M, Kim EJ, Kim B, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch. Dermatol. 146, 780–784 (2010).
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J. Rheumatol. 37, 1549–1550 (2010).
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Yukawa N, Kawabata D et al. A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin. Rheumatol. 30, 429–432 (2010).
   Web of Science ®Google Scholar
• Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7(3), R666–R676 (2005).
   PubMed Web of Science ®Google Scholar
• Urata Y, Wakai Y, Kowatari K, Nitobe T, Mizushima Y. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod. Rheumatol. 16(6), 410–411 (2006).
   PubMedGoogle Scholar
• Musial J, Undas A, Celiñska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42(12), 1566–1568 (2003).
   PubMed Web of Science ®Google Scholar
• Riolo G, Towheed TE. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J. Rheumatol. 39(1), 192–194 (2012).
   PubMed Web of Science ®Google Scholar
• Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann. Rheum. Dis. 62( Suppl. 2), ii30–ii33 (2003).
   PubMedGoogle Scholar
• Liozon E, Ouattara B, Loustaud-Ratti V, Vidal E. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand. J. Rheumatol. 36(6), 484–486 (2007).
   PubMed Web of Science ®Google Scholar
• Kiltz U, Fendler C, Braun J. Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy – three examples. J. Rheumatol. 35(10), 2074–2076 (2008).
   PubMed Web of Science ®Google Scholar
• Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 55(6), 982–984 (2006).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best. Pract. Res. Clin. Rheumatol. 22(5), 847–861 (2008).
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta. Derm. Venereol. 90(2), 183–185 (2010).
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Massone C. Is dermatomyositis in patients with rheumatoid arthritis induced by anti-TNF-alpha therapy? Clin. Rheumatol. 30(3), 439–440 (2011).
   PubMed Web of Science ®Google Scholar
• Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47(6), 877–880 (2008).
   PubMed Web of Science ®Google Scholar
• Alzabin S, Abraham SM, Taher TE, et al. Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway. Ann. Rheum. Dis. 71(10), 1741–1748 (2012).
   PubMed Web of Science ®Google Scholar
• Dahl C, Johansen C, Kragballe K, Olesen AB. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta. Derm. Venereol. 93(3), 368–369 (2013).
   PubMed Web of Science ®Google Scholar
• Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus 21(9), 1007–1010 (2012).
   PubMed Web of Science ®Google Scholar
• De Souza A, Ali-Shaw T, Strober BE, Franks AGJr. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch. Dermatol. 147(8), 896–898 (2011).
   PubMedGoogle Scholar
• Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch. Dermatol. 147(7), 831–835 (2011).
   PubMedGoogle Scholar
• de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]. Acta Reumatol. Port. 32(2), 139–150 (2007).
   PubMed Web of Science ®Google Scholar